|Bid||84.21 x 900|
|Ask||86.70 x 800|
|Day's Range||85.57 - 88.01|
|52 Week Range||56.19 - 113.06|
|PE Ratio (TTM)||N/A|
|YTD Daily Total Return||-4.88%|
|Beta (5Y Monthly)||1.82|
|Expense Ratio (net)||0.95%|
Read a comparison of BIB and LABU and a description of the characteristics and historical performance of these leveraged biotech ETFs.
Marc Lichtenfeld, an expert in biotech and income stocks, notes that a lot of Wall Street money moves into companies that issue positive Phase 2 clinical trial data.
Nasdaq Stock Exchange President Nelson Griggs joins Yahoo Finance’s Seana Smith to discuss market operations amid the coronavirus and the outlook on IPOs.